PUBLIC COMPANY
save$TVTXTravere Therapeutics, Inc.
$TVTX56.93+0.14%San Diego, CA, USupdated 1d ago
Martin Shkreli is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
community read0 votes
pipeline
3
marketed
1
phase 3
1
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 31Marketed1Unknown
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase3Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care Treatment
- phase3A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
- phase3Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS)
- phase4Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis
- phase2Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
- phase2A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN
- phase2Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
- phase3A Phase 3 Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE)
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 22, 26SELLROTE WILLIAM E.· Chief Research Officer−$356K↗
- Apr 15, 26SELLDube Eric M· CHIEF EXECUTIVE OFFICER−$2.33M↗
- Apr 15, 26SELLDube Eric M· CHIEF EXECUTIVE OFFICER−$299K↗
- Apr 15, 26SELLREED ELIZABETH E· Chief Legal Officer and GC−$218K↗
- Apr 15, 26SELLREED ELIZABETH E· Chief Legal Officer and GC−$66K↗
- Apr 15, 26SELLInrig Jula· CHIEF MEDICAL OFFICER−$43K↗
- Apr 15, 26SELLCline Christopher R.· CHIEF FINANCIAL OFFICER−$43K↗
- Apr 15, 26SELLDube Eric M· CHIEF EXECUTIVE OFFICER−$853↗
- Apr 14, 26SELLREED ELIZABETH E· Chief Legal Officer and GC−$1.54M↗
- Apr 14, 26SELLBaynes Roy D.· −$1.07M↗
- Apr 14, 26SELLCalvin Sandra· SVP, CHIEF ACCOUNTING OFFICER−$903K↗
- Apr 14, 26SELLLYONS GARY A· −$329K↗
- Apr 14, 26SELLCline Christopher R.· CHIEF FINANCIAL OFFICER−$304K↗
- Apr 14, 26SELLHeerma Peter· CHIEF COMMERCIAL OFFICER−$303K↗
- Apr 14, 26SELLInrig Jula· CHIEF MEDICAL OFFICER−$303K↗
- Apr 14, 26SELLREED ELIZABETH E· Chief Legal Officer and GC−$303K↗
- Apr 14, 26SELLBaynes Roy D.· −$284K↗
- Apr 14, 26SELLCline Christopher R.· CHIEF FINANCIAL OFFICER−$370↗
- Apr 13, 26SELLCline Christopher R.· CHIEF FINANCIAL OFFICER−$2K↗
routine RSU / option mechanics (1)
- Apr 14, 26option exerciseREED ELIZABETH E · Chief Legal Officer and GC20,000 sh
🐶 Hiring Signal
next earnings Oct 29, 2026
News
- Travere pays Everest $112M upfront to grow rare kidney disease pipelineTravere Therapeutics is enlisting the help of China-based Everest Medicines to bolster its rare kidney disease pipeline beyond its approved medicine Filspari. The San Diego biotech is doling out $1…endpoints · 4mo ago
Data sources
last refreshed 41m ago
Found something off?
comments(0)
5-min edit window · permanent after that